Hosted on MSN1d
GenSight’s Optic Neuropathy gene therapy sustains efficacy over five years
The five-year trial saw patients who received a single injection of Lumevoq sustaining clinical recovery in a rare condition ...
MSC-mediated mitochondrial transfer holds therapeutic promise for Leber's hereditary optic neuropathy patients
More information: Rui Wang et al, MSC-mediated mitochondrial transfer restores mitochondrial DNA and function in neural ...
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing a ...
Healthline24d
Understanding Optic Neuritis
when part of your optic nerve is not getting enough blood Leber hereditary optic neuropathy, a type of vision loss that is passed down in families A doctor can assess your symptoms and use tests ...
Business Wire1mon
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ ® Gene Therapy
About Leber Hereditary Optic Neuropathy (LHON ... which are derived from the number of letters patients read on the ETDRS chart, were used for statistical purposes. Both trials were adequately ...
pharmaphorum13d
LHON in the family: living under the spectre of an hereditary eye disease
It’s hard to imagine suddenly losing your sight in your 20s, but that’s what happened to Richard Wheeler when he developed Leber’s hereditary optic neuropathy (LHON). People with LHON ...
Pharmabiz1d
GenSight Biologics announces efficacy and safety results for Lumevoq gene therapy at the conclusion of the REFLECT phase III clinical study
GenSight Biologics announces efficacy and safety results for Lumevoq gene therapy at the conclusion of the REFLECT phase III clinical study: Paris Thursday, February 13, 2025, 17: ...